The global bioprocess automation software market size is projected to reach USD 3.84 billion by 2033, growing at a CAGR of 13.84% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is largely driven by the growing adoption of digitalization and automation across the biopharmaceutical manufacturing sector. As companies strive to improve efficiency, reproducibility, and scalability, automation software enables seamless integration of upstream and downstream processes. Platforms like MES, SCADA, and LIMS allow manufacturers to reduce manual interventions, streamline workflows, and maintain compliance with stringent regulatory standards, making automated solutions essential for modern biologics production.
Another key driver is the increasing demand for real-time monitoring and advanced data analytics in bioprocessing. Automation software equipped with sensors, process analytical technology (PAT), and AI-driven analytics enables manufacturers to track critical parameters, detect deviations early, and make data-driven adjustments. This capability improves product quality, minimizes batch failures, and accelerates development timelines, supporting both commercial and clinical manufacturing objectives.
Finally, the expansion of global biomanufacturing and the rise of contract development and manufacturing organizations (CDMOs) are fueling market growth. These organizations handle multiple client projects simultaneously, making integrated automation software critical for maintaining operational efficiency, consistency, and regulatory compliance. The trend toward continuous bioprocessing, single-use systems, and digital laboratories further reinforces the need for intelligent, scalable software solutions capable of supporting end-to-end bioprocess operations.
Request a free sample copy or view report summary: Bioprocess Automation Software Market Report
By type, the process analytical technology segment was the market leader with 31.50% share in 2024, as it enables real-time, data-driven control of critical quality attributes during biologics production.
By application, the downstream processing segment dominated the market in 2024 with a share of 33.34%. The increasing focus on improving efficiency and product recovery in downstream processing is a major driver of the bioprocess automation software market.
By end use, pharmaceutical and biotech manufacturers held the largest share of the bioprocess automation market in 2024, accounting for 36.24%. Their demand for efficient, reproducible, and compliant bioprocessing systems is vital to the establishment of large-scale operations for biologics, vaccines, and advanced therapies.
Grand View Research has segmented the global bioprocess automation software market on the basis of type, application, end use, and region.
Bioprocess Automation Software Type Outlook (Revenue, USD Million, 2021 - 2033)
Distributed Control Systems
Supervisory Control and Data Acquisition
Manufacturing Execution Systems
Laboratory Information Management Systems
Process Analytical Technology
Bioprocess Automation Software Application Outlook (Revenue, USD Million, 2021 - 2033)
Upstream Processing
Downstream Processing
Quality Control
Manufacturing Operations
Data Management
Bioprocess Automation Software End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceutical & biotech manufacturers
CDMOs & CMOs
Academic & research institutions
Contract testing & analytical labs
Others
Bioprocess Automation Software Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
India
Japan
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Bioprocess Automation Software Market
Thermo Fisher Scientific, Inc.
Rockwell Automation
Agilitech
Amgen
Andrew Alliance (Waters)
Synthace
Merck KGaA
Eppendorf SE
Bioengineering AG
"The quality of research they have done for us has been excellent..."